[go: up one dir, main page]

PL2437748T3 - Skojarzone preparaty zawierające antagonistę cytokin i kortykosteroid - Google Patents

Skojarzone preparaty zawierające antagonistę cytokin i kortykosteroid

Info

Publication number
PL2437748T3
PL2437748T3 PL10800714T PL10800714T PL2437748T3 PL 2437748 T3 PL2437748 T3 PL 2437748T3 PL 10800714 T PL10800714 T PL 10800714T PL 10800714 T PL10800714 T PL 10800714T PL 2437748 T3 PL2437748 T3 PL 2437748T3
Authority
PL
Poland
Prior art keywords
corticosteroid
combination preparation
cytokine antagonist
cytokine
antagonist
Prior art date
Application number
PL10800714T
Other languages
English (en)
Inventor
Peter Wehling
Julio Reinecke
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of PL2437748T3 publication Critical patent/PL2437748T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/19Platelets; Megacaryocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5176Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184Virus capsids or envelopes enclosing drugs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
PL10800714T 2009-12-10 2010-12-10 Skojarzone preparaty zawierające antagonistę cytokin i kortykosteroid PL2437748T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102009057495 2009-12-10

Publications (1)

Publication Number Publication Date
PL2437748T3 true PL2437748T3 (pl) 2017-09-29

Family

ID=43707934

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10800714T PL2437748T3 (pl) 2009-12-10 2010-12-10 Skojarzone preparaty zawierające antagonistę cytokin i kortykosteroid
PL10800713T PL2437747T3 (pl) 2009-12-10 2010-12-10 Preparaty łączone z egzosomami i kortykosteroidem

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10800713T PL2437747T3 (pl) 2009-12-10 2010-12-10 Preparaty łączone z egzosomami i kortykosteroidem

Country Status (22)

Country Link
US (3) US9724391B2 (pl)
EP (2) EP2437748B8 (pl)
JP (2) JP5984674B2 (pl)
KR (2) KR20120109542A (pl)
CN (2) CN102655868A (pl)
AU (2) AU2010340999B2 (pl)
BR (2) BR112012013888A2 (pl)
CA (2) CA2781576C (pl)
CY (2) CY1118081T1 (pl)
DE (1) DE202009017772U1 (pl)
DK (2) DK2437747T3 (pl)
ES (2) ES2594896T3 (pl)
HR (2) HRP20161279T1 (pl)
HU (2) HUE030460T2 (pl)
LT (2) LT2437747T (pl)
MX (2) MX2012006430A (pl)
PL (2) PL2437748T3 (pl)
PT (2) PT2437748T (pl)
RS (2) RS55251B1 (pl)
RU (2) RU2526161C2 (pl)
SI (2) SI2437747T1 (pl)
WO (2) WO2011082950A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170189475A9 (en) * 2009-12-10 2017-07-06 Orthogen Ag Combination preparation comprising a cytokine antagonist and corticosteroid
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN104673749B (zh) * 2015-02-12 2017-10-20 江苏大学 一种粒细胞样髓源性抑制细胞来源exosomes及其应用
TW201722442A (zh) * 2015-11-13 2017-07-01 奧爾托金公司 對老化相關病症有效之醫藥製劑
HK1258712A1 (zh) * 2016-08-17 2019-11-15 Orthogen Ag 抗衰老药物制剂
CA3073137A1 (en) 2016-08-19 2018-02-22 Jeffrey S. Bartlett Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
WO2018056481A1 (ko) * 2016-09-23 2018-03-29 ㈜프로스테믹스 면역 억제 및 항염증성 조성물
MX2019006614A (es) 2016-12-07 2019-10-15 Univ Florida Adnc del antagonista del receptor de interleucina-1.
CN108175759B (zh) * 2016-12-08 2021-03-19 暨南大学 一种抗肿瘤靶向给药系统及其制备方法与应用
EA038300B1 (ru) * 2017-04-18 2021-08-06 Юниверсити Оф Флорида Рисерч Фаундейшен, Инкорпорейтед Кднк il-1ra
CN108619114B (zh) * 2018-05-02 2020-08-11 东南大学 一种负载地塞米松的巨噬细胞源微囊泡及其制备方法和应用
CN109078171A (zh) * 2018-09-10 2018-12-25 因之彩生物科技(武汉)有限公司 一种外用组合物及其应用以及外用治疗剂
MX2021009485A (es) * 2019-02-07 2021-09-23 Direct Biologics Llc Metodo para el tratamiento de la osteoartritis con una combinacion de exosomas de celulas madre mesenquimales, celulas madre mesenquimales sinoviales, y soportes.
WO2025024729A1 (en) * 2023-07-27 2025-01-30 Rush University Medical Center Novel chitosan-il-36ra conjugates for adjustable, sustained release and tissue distribution
KR20250042870A (ko) * 2023-09-20 2025-03-28 주식회사 씨케이엑소젠 연골 항상성 인자를 포함하는 엑소좀 및 이를 포함하는 피부 또는 연골 재생용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793159A (en) * 1955-03-09 1957-05-21 Upjohn Co Stable hydrocortisone solution
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
IL110589A0 (en) 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
EA001792B1 (ru) 1996-02-09 2001-08-27 Амген Инк. Композиция, включающая ингибитор il-1 и гидрогелевый эфир, и способы ее применения
DE69726884T2 (de) * 1997-02-06 2004-06-03 Genetics Institute, LLC, Cambridge Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
JP4038331B2 (ja) 1997-08-16 2008-01-23 オルソゲン アーゲー 治療効果を有するタンパク質を誘導するための方法
DE19903876B4 (de) 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
DE10213780A1 (de) 2002-03-22 2003-11-27 Orthogen Ag Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen
AU2005262319A1 (en) 2004-07-01 2006-01-19 Orthogen Ag Immunosuppressive exosomes
DE102004036840B4 (de) 2004-07-29 2012-04-19 Orthogen Ag Verfahren und Mittel zur Gewinnung von thrombocytenreichem Plasma
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
WO2007008155A1 (en) 2005-07-11 2007-01-18 Astrazeneca Ab New combination 1
US7292185B2 (en) * 2005-10-04 2007-11-06 Csi Wireless Inc. Attitude determination exploiting geometry constraints
EP1956906A4 (en) * 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
DE102006005016A1 (de) 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
CA2781576A1 (en) 2011-07-14
DK2437748T5 (en) 2016-12-05
US8828946B2 (en) 2014-09-09
KR101786444B1 (ko) 2017-10-18
RU2526161C2 (ru) 2014-08-20
HUE029979T2 (en) 2017-04-28
BR112012013888A2 (pt) 2017-03-07
HUE030460T2 (en) 2017-05-29
JP5984674B2 (ja) 2016-09-06
EP2437748B8 (de) 2016-10-19
US10537614B2 (en) 2020-01-21
CN102655868A (zh) 2012-09-05
MX2012006430A (es) 2012-07-30
JP2013513582A (ja) 2013-04-22
CN102652020A (zh) 2012-08-29
BR112012014066A2 (pt) 2017-04-04
WO2011082950A1 (de) 2011-07-14
EP2437747A1 (de) 2012-04-11
HRP20161268T1 (hr) 2016-11-04
AU2010341000A1 (en) 2012-06-21
DK2437748T3 (en) 2016-10-24
MX2012006206A (es) 2012-06-28
KR20120109542A (ko) 2012-10-08
KR20120107108A (ko) 2012-09-28
RS55251B1 (sr) 2017-02-28
AU2010340999B2 (en) 2014-08-14
US20120237587A1 (en) 2012-09-20
EP2437747B8 (de) 2016-10-19
JP5907886B2 (ja) 2016-04-26
CA2781223C (en) 2016-02-16
LT2437747T (lt) 2016-10-25
CA2781223A1 (en) 2011-07-14
US20120237525A1 (en) 2012-09-20
PT2437747T (pt) 2016-10-18
EP2437748A1 (de) 2012-04-11
CY1118081T1 (el) 2017-06-28
WO2011082951A1 (de) 2011-07-14
SI2437748T1 (sl) 2016-12-30
HRP20161279T1 (hr) 2016-12-02
PL2437747T3 (pl) 2017-01-31
JP2013513583A (ja) 2013-04-22
CY1118044T1 (el) 2017-05-17
AU2010341000B2 (en) 2014-08-14
RU2012128776A (ru) 2014-01-20
EP2437748B1 (de) 2016-08-31
US20190038719A1 (en) 2019-02-07
ES2594896T3 (es) 2016-12-23
CA2781576C (en) 2016-02-09
SI2437747T1 (sl) 2016-12-30
DE202009017772U1 (de) 2011-04-21
AU2010340999A1 (en) 2012-06-21
DK2437747T3 (en) 2016-10-24
LT2437748T (lt) 2016-11-10
PT2437748T (pt) 2016-10-14
US20130164303A2 (en) 2013-06-27
CN107096031A (zh) 2017-08-29
RU2012128877A (ru) 2014-01-20
ES2594766T3 (es) 2016-12-22
RU2557897C2 (ru) 2015-07-27
EP2437747B1 (de) 2016-08-31
US9724391B2 (en) 2017-08-08
RS55217B1 (sr) 2017-02-28

Similar Documents

Publication Publication Date Title
SI2437748T1 (sl) Kombinacijski pripravek z antagonistom citokina in kortikosteroidom
SG10201404662YA (en) Dp2 antagonist and uses thereof
IL239997A (en) Certain triazolopyridines and certain triazolopyrazines and their preparations and uses
ZA201202029B (en) Androgen receptor antagonists and uses thereof
IL216374A0 (en) Compositions and methods for drug delivery
IL218498A (en) Ketone-adapted opioid drug adjuvants, method of preparation, preparations containing them and their use
IL214145A0 (en) Solid pharmaceutical composition comprising amlodipine and losartan
IL219279A0 (en) Corticosteroid and anti-cd56-maytansinoid conjugate dosing regimens and uses thereof
ZA201106831B (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
IL218212A0 (en) Therapeutic methods and compositions
IL215813A0 (en) Pariticulate pharmaceutical composition with an opioid and an opioid antagonist
ZA201200079B (en) Pharmaceutical compositions and solid forms
GB0902429D0 (en) Compositions and their use
IL219987A0 (en) Dp2 antagonist and uses thereof
EP2501390A4 (en) COMPOSITIONS AND METHODS OF ACTIVITY ON CYTOKINS AND NF-KB
GB0920125D0 (en) Delivery device and delivery methods
EP2461870A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
ZA201200260B (en) Polyphenylsulphone-polytetrafluroethylene compositions and use thereof
EP2421747A4 (en) NETWORK AND LINEN CUTTING DEVICE
AP2788A (en) Simalikalactone E and use thereof as a medicament
HK1172007A (en) Dp2 antagonist and uses thereof
GB0906703D0 (en) Excipients and their use
GB0906046D0 (en) Nalmefene compositions and their therapeutic use
GB0906043D0 (en) Nalmefene compositions and their therapeutic use
GB0906045D0 (en) Nalmefene compositions and their therapeutic use